FEB 2 5 2005

PTO/SB/21 (04-04)
Approved for use through 07/31/2006. OMB 0851-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paper Reduction Act of 1885, no persons are required to respond to a collection of information unless it displays a valid OMB control number. Application Number 10/814,399 TRANSMITTAL Filing Date 03/31/2004 FORM Inventor Steven C. Quay et al. (to be used for all correspondence after initial filing) Art Unit 1623 **Examiner Name** Total Number of Pages in This Submission **Attorney Docket Number** 03-02CIP ENCLOSURES (Check all that apply) Fee Transmittal Form After Allowance communication to Technology Center (TC) Drawing(s) Fee Attached \$65 Licensing-related Papers Appeal Communication to Board of Appeals and Interferences Amendment / Reply Petition Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) Request to Correct Priority Petition to Convert to a Proprietary Information Claim Provisional Application Affidavits/declaration(s) Declaration and Power of Attorney. Status Letter Declaration, 2 pages **Extension of Time Request** Other Enclosure(s) (please identify below): Terminal Disclaimer Express Abandonment Request Request for Refund Substitute page one of form 1449A/PTO Substitute Information CD, Number of CD(s) Disclosure Statement Certified Copy of Priority We recently filed an IDS of 3 pages with references on Document(s) 1/14/2005. We noted a typographical error on page 1. The Response to Missing Parts/ Incomplete Application Mayor Pharmaceutical Laboratories US patent number has Response to Missing Parts under 37 CFR 1.52 or 1.53 been corrected from 4,523,341 to the correct patent number of 4,525,341. Kindly switch out the prior page one of form 1449A/PTO for this new page one. Thank you. SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Nastech Pharmaceutical Company Inc., Paul G. Lunn, Attorney, Registration No. 32,743 Individual name Signature Date February 25, 2005 CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being facsimile transmitted to the USPTO to the Fax number 703-872-9306 on the date shown Typed or printed name Jeffrey L. Granger Signature Date February 25, 2005

This collection of information is residied by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

RECEIVED CENTRAL FAX CENTER

FEB 2 5 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Quay et al.

Attorney Docket No.: 03-02CIP

Serial No.: 10/814,399

Group Art Unit: 1623

Filed: 3/31/2004

Examiner: unknown

Title: CYANOCOBALAMIN LOW

VISCOSITY AQUEOUS FORMULATIONS FOR INTRANASAL DELIVERY

Commissioner for Patents P.O. Box 1450

Alexandria, VA 22313-1450

SUBSTITUTE INFORMATION DISCLOSURE STATEMENT

Dear Sir:

This Information Disclosure Statement is submitted:

- X under 37 CFR 1.97(b), or (Within three months of filing national application; or date of entry of international application; or before mailing date of first office action on the merits; whichever occurs last)
- under 37 CFR 1.97(c) together with either a:
 - Statement under 37 CFR 1.97(e), or
 - a \$180.00 fee under 37 CFR 1.17(p), or
 - (After the CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)
- under 37 CFR 1.97(d) together with a:
 - Statement under 37 CFR 1.97(e), and
 - a \$180.00 fee set forth in 37 CFR 1.17(p).
 - (Filed after final action or notice of allowance, whichever occurs first, but before payment of the issue fee)

Applicant(s) submit herewith a substitute Form PTO 1449-Information Disclosure Citation page one only.

Applicants also wish to bring to the attention of the Examiner that the assignee previously prosecuted patent application no. 06/723,859, entitled "Aerosol Compositions for Nasal Delivery of Vitamin B12," filed April 16, 1985, which was abandoned by the assignee.

The relevance of the attached references is that this is the closest art of which Applicant is aware. Applicant submits that the above references taken alone or in combination neither anticipate nor render obvious the present invention. Consideration of the foregoing in relation to this application is respectfully requested.

It is requested that the information disclosed herein be made of record in this application.

I hereby certify that this Correspondence is being facsimile transmitted to the USPTO, fax number 703-872-9306, on the date indicated below.

Date of Deposit: February 25, 2005

Typed Name: Jeffrey L. Granger

Signature

Respectfully submitted,

Paul G. Lunn

Attorney/Agent for Applicant(s)

Reg. No. 32743

Date: February 25, 2005

Telephone No.: (425) 908-3643

Approved for use through 07/31/2088. OMR need 00-03)

Under 6	he Paperwork Reduction Art o	f 1995, no perso	ns are required to	U.S. Patent and Trade respond to a collection of information	mark Office: U.S. DEPARTMENT OF COMMERCI ation unless it displays a valid OMB control number		
Substitute for form 1449A/PTO				Complete if Known			
				Application Number	10/814,399		
INFORMATION DISCLOSURE				Filing Date	03/31/2004		
S.	TATEMENT BY	APPLIC.	ΔNT	First Named Inventor	Steven C. Quey of el.		
			714 [Art Unit	1623		
(Use as many sheets as necessary)				Examiner Name			
Sheet	1	of	3	Attorney Docket Number	03-02CIP		

Exeminer	5145	Document Number		T DOCUMENTS	· · · · · · · · · · · · · · · · · · ·		
mittels*	Cite No.	Number - Kind Code ² (If known)	issued Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
		US- 2,703,302	03-01-1955	Merck & Co. inc.			
		US- 2,703,303	03-01-1955	Merck & Co., Inc.			
	~***	US- 2,746,798	05-22-1956	The Pharma-Craft Corporation			
		US- 2,914,222	11-24-1959	Philip Meshberg			
		US- 3,000,793	09-19-1961	Merck & Co., Inc.			
		US- 2,951,017	08-30-1960	The Distillers Company Umited			
		U\$- 3,057,861	10-09-1962	Armour Pharmaceutical			
		US- 3,018,225	01-23-1962	Merck & Co., Inc.			
		US- 3,120,509	02-04-1984	Hoffmann-La Roche Inc.	4.5 14.		
		US- 3,282,781	11-01-1966	Merck & Co., Inc.			
		US- 3,548,057	12-15-1970	Merck & Co., Inc.			
		US- 3,577,537	05-04-1971	Merck & Co., Inc			
		US- 3.584,115	08-08-1971	Arthur I. Gebhari & Angelo T. Bonduris			
·		US- 3,957,966	05-18-1976	GAF Corporation			
		US- 4,174,295	11-13-1979	Montedison S.p.A.			
		US- 4,525,341	06-25-1985	Mayor Pharmaceutical Laboratories			
		US- 4,724,231	02-09-1988	Nastech Pharmacoutical, Inc.			
		US- 5,801,161	09-01-1998	Merkus, Franciscus			
		US- 5,797,390	08-25-1998	McSoley, Thomas E.			
		US- 5,925,625	07-20-1999	Merkus, Francicus			
		US- 6,685,421	12-16-2003	Image Therm Engineering, Inc.			

	_	FOREIG	N PATENT DOC	UMENTS		_
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ - Number - Kind Code ⁵ (# known) EP 0131315 A2	Issue Date MM-DD-YYYY	Name of Patentize or Applicant of Cited Document	Pages, Columns, Unes, Where Relevant Passages or Relevant Figures Appear	тв
		PCT WO 86/05988 (International Application Number PCT/US86/00793)	02-15-1984 08-27-1984	Istituto De Angell Insternedical GmbH	Or Agevant Figures Appear	
			10-23-1986 Publication Date	Nastech Pharmaceutical Company, Inc.		+
		PCT WO 86-05987 (International Application Number PCT/US86/00865)	10-23-1986 Publication Date	Nastech Pharmaceutical Company, Inc.		\vdash
						╁—

		1	
Examiner			1 (
Signature	Date		_
*EVALUATED TO THE TOTAL	Concidents		

'EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw time through citation if not in conformance and not use? To Patent Documents at wow.uspto.nov or MPEP 901.04. 3Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4For use patent documents, the indication of the year of the reign of the Emperor must precede the sental number of the patent document. 5Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6Applicant is to place a check mark here if English language That of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to fite (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the Individual case. Any comments and Tradernark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS Standards, VA 22313-1450.

if you need assistance in completing the form, call 1-800-PTO-9189 and select option 2.